Loading...
•
Jun 30, 2023
Trevena Q2 2023 Earnings Report
Trevena reported second quarter 2023 results and provided a business update.
Key Takeaways
Trevena reported net revenue of $3.0 million and a net loss attributable to common stockholders of $8.0 million, or $0.69 per share, for the second quarter of 2023. They anticipate a $15 million non-dilutive tranche from R-Bridge in Q3 2023.
Database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy announced; topline data expected 3Q 2023.
TRV045 proof-of-concept study evaluating potential for use in acute and chronic pain advancing with topline data expected 3Q 2023.
New respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023.
OLINVYK-treated patients had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV opioids in the ARTEMIS study.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...